StoxMedicamen Organics Limited
NSE: MEDIORG · Unclassified
Ask the data
Instant answers about Medicamen Organics Limited — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY25 | FY26 | |
|---|---|---|
| Revenue | 38.2 | 22.6 |
| EBITDA | 6.6 | -3.8 |
| Operating margin | 17.3% | -16.6% |
| Interest | 0.5 | 0.7 |
| Depreciation | 0.7 | 0.9 |
| Profit before tax | 5.4 | -5.3 |
| Tax | 1.4 | -1.3 |
| Net profit | 4.0 | -4.0 |
| EPS ₹ | 3.67 | -3.41 |
| Operating cash flow | 0.9 | -4.6 |
| Capex | 0.0 | 1.7 |
| Dividend paid | 0.0 | 0.0 |
| Total assets | 59.2 | 51.6 |
| Equity | 30.1 | 28.7 |
Half-yearly performance
last 4 half years · ₹ crore| H1 FY25* | H2 FY25 | H1 FY26 | H2 FY26 | |
|---|---|---|---|---|
| Revenue | 16.6 | 21.6 | 17.9 | 4.8 |
| Operating profit | 2.7 | 3.9 | 3.4 | -7.2 |
| Operating margin | 16.5% | 17.8% | 19.2% | -150.2% |
| Other income | 0.1 | 0.1 | 0.1 | 0.0 |
| Interest | 0.2 | 0.3 | 0.3 | 0.4 |
| Depreciation | 0.4 | 0.4 | 0.4 | 0.5 |
| Profit before tax | 2.2 | 3.2 | 2.7 | -8.0 |
| Tax | 0.7 | 0.7 | 0.7 | -2.0 |
| Net profit | 1.5 | 2.5 | 2.0 | -6.1 |
| EPS ₹ | 1.48 | 2.19 | 1.74 | -5.15 |
| Revenue YoY | — | — | 7.5% | -77.8% |
| Profit YoY | — | — | 35.1% | -338.6% |
Returns & margins
trailing-twelve-month, per half year| H2 FY25 | H1 FY26 | H2 FY26 | |
|---|---|---|---|
| ROE | 13.4% | 14.0% | -14.0% |
| ROCE | 14.0% | 13.7% | -10.6% |
| Net margin | 10.6% | 11.6% | -17.8% |
| EBITDA margin | 17.3% | 18.5% | -16.6% |
| Debt / equity | 0.41 | 0.48 | 0.50 |
| Interest coverage | 11.65 | 10.65 | -6.44 |
| Asset turnover | 0.64 | 0.64 | 0.44 |
Balance sheet
equity vs borrowings over time · ₹ crore| MAR '25 | SEP '25 | MAR '26 | |
|---|---|---|---|
| Share capital | 11.7 | 11.7 | 12.2 |
| Other equity / reserves | 17.7 | 19.7 | 16.6 |
| Total equity | 30.1 | 32.6 | 28.7 |
| Borrowings | 12.3 | 15.7 | 14.3 |
| Current liabilities | 27.2 | 26.3 | 21.8 |
| Non-current liabilities | 1.6 | 1.8 | 1.3 |
| Total assets | 59.2 | 61.1 | 51.6 |
| Property, plant & equipment | 10.1 | 12.7 | 12.8 |
| Investments | 0.0 | 0.0 | 0.0 |
| Inventories | 7.5 | 8.2 | 10.5 |
| Receivables | 25.9 | 28.1 | 18.6 |
| Cash & equivalents | 4.1 | 2.9 | 1.3 |
Cash flow
annual · ₹ crore · line = free cash flow| FY25 | FY26 | |
|---|---|---|
| Cash from operations | 0.9 | -4.6 |
| Cash from investing | 0.1 | -1.7 |
| Cash from financing | 3.3 | 3.5 |
| Capex | 0.0 | 1.7 |
| Free cash flow | 0.9 | -6.3 |
| Dividends paid | 0.0 | 0.0 |
Where the assets sit
Mar '26 · ₹ crorePeer comparison
largest in Unclassified · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Avantel Limited | 36,86,04,549 | 138.69 | — | 1059360.68 | 0.0% |
| Ducol Organics And Colours Limited | 19,55,275 | 120.00 | — | 20089.13 | 0.0% |
| Jio Platforms Limited | 12,57,181 | 1,406.40 | — | 3.57 | — |
| SBI Funds Management Limited | 1,01,750 | 499.55 | — | — | — |
| Tamilnadu Telecommunication Limited | 91,314 | 9.93 | — | — | — |
| Manipal Health Enterprises Limited | 76,294 | 646.70 | — | — | — |
| INDO-MIM Limited | 59,042 | 1,219.50 | — | — | — |
| AvenuesAI Limited | 45,138 | 129.25 | 153.6 | 9.51 | 6.2% |
| Dhoot Transmission Limited | 32,761 | 1,601.60 | — | 8.11 | — |
| 3M India Limited | 31,071 | 27,570.00 | 53.8 | 17.57 | 32.7% |
| Medicamen Organics Limited | 30 | 25.90 | — | 1.05 | -14.0% |
StoxGud checklist: Neutral setup · 4/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
FAQs
What is the share price of Medicamen Organics Limited?
Medicamen Organics Limited (MEDIORG) closed at ₹25.90 on NSE on 02 Nov 2026.
What is the market cap of Medicamen Organics Limited?
₹30 crore at the latest close.
How fast is Medicamen Organics Limited growing?
Medicamen Organics Limited: Latest-half-year revenue is down 77.8% year on year, profit down 338.6%.
How profitable is Medicamen Organics Limited?
On a trailing-twelve-month basis return on equity is -14.0%, return on capital employed -10.6%, operating margin -16.6%, net margin -17.8%.
How much debt does Medicamen Organics Limited have?
Medicamen Organics Limited is lightly geared: debt to equity is 0.50 with borrowings of ₹14 cr against cash of ₹1 cr (balance sheet of 2026-03-31). Operating profit covers interest -6.4 times.
Financials parsed from Medicamen Organics Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Half-yearly from H1 FY25, annual from FY25, balance sheet from Mar '25. * = derived (full year minus the other half). This company is on NSE's SME platform and reports results half-yearly. Information only, not investment advice.